As the majority of patients present with IVC disease or develop distant metastasis during the course of disease progression, our data suggest that neoadjuvant BRAF-directed therapy results in a systemic reduction in tumor burden to allow for surgical resection of primary disease. This evidence concerns the gene BRAF and neoplasm.